ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation
31 juil. 2018 08h30 HE
|
ARCA biopharma, Inc.
Single Phase 3 trial may be sufficient for approval of atrial fibrillation indicationPhase 3 clinical trial Special Protocol Assessment submission anticipated 3Q2018Gencaro is in development as...
BioSig Technologies to Present at the Emerging Medical Technologies Spotlight
29 juin 2018 08h00 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, June 29, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to...
BioSig Technologies to Present at the 8th Annual LD Micro Invitational
01 juin 2018 12h55 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, June 01, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical technology company developing a proprietary biomedical signal processing platform designed to...
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
29 mai 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Phase 2B GENETIC-AF Clinical Trial Results Selected for Late Breaking Oral Presentation at European Society of Cardiology Heart Failure 2018 World Congress
10 mai 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 10, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
BioSig Technologies Announces Acceptance of Paper for the 40th International Conference of the IEEE Engineering in Medicine and Biology Society
09 mai 2018 08h00 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, May 09, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update
08 mai 2018 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Sim Farar Joins BioSig Technologies Advisory Board
08 mai 2018 08h00 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, May 08, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
BioSig Technologies Completes Private Placement
01 mai 2018 08h00 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, May 01, 2018 (GLOBE NEWSWIRE) --
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed...
ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement
23 avr. 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 23, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...